# Decera Clinical Education Oncology Podcast Page: https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999 Text version: https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999.md RSS feed: https://feeds.simplecast.com/GlfUTtJq Official site: https://oncologypodcast.simplecast.com Author: Decera Clinical Education Episodes: 253 ## Resource Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes. ## Machine-readable JSON: https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999 Markdown: https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999.md ## Episodes - [Beyond BCMA: How GPRC5D-Targeted Therapy Fits Iinto Multiple Myeloma Care Today](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today) — 2026-07-14T13:12:51+00:00 - [What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma) — 2026-07-13T19:28:33+00:00 - [Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer) — 2026-06-30T18:57:34+00:00 - [Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/personalizing-egfr-mutation-positive-nsclc-care-strategies-for-the-advanced-practice-provider) — 2026-06-22T15:16:16+00:00 - [Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness) — 2026-06-09T17:23:16+00:00 - [HNSCC: Current and Emerging Therapeutic Strategies](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/hnscc-current-and-emerging-therapeutic-strategies) — 2026-05-29T21:01:30+00:00 - [Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies) — 2026-05-15T19:36:02+00:00 - [Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma) — 2026-05-07T13:14:37+00:00 - [Thrombotic Events and ET/PV: What You Should Know](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/thrombotic-events-and-et-pv-what-you-should-know) — 2026-04-30T20:15:58+00:00 - [Global Experts Discuss Current and Emerging Treatments for ET and PV](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv) — 2026-04-30T20:08:16+00:00 - [Global Experts Discuss Diagnostic Considerations in ET and PV](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-diagnostic-considerations-in-et-and-pv) — 2026-04-29T20:02:34+00:00 - [Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer) — 2026-04-17T18:05:54+00:00 - [Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-voices-caring-for-the-whole-patient-and-personalizing-treatment-of-early-breast-cancer-to-achieve-equitable-outcomes) — 2026-04-15T20:55:22+00:00 - [Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities) — 2026-04-15T17:57:46+00:00 - [Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer) — 2026-04-14T19:56:16+00:00 - [TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions) — 2026-04-13T15:40:27+00:00 - [Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer) — 2026-04-13T15:01:24+00:00 - [Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc) — 2026-03-26T13:13:16+00:00 - [Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer) — 2026-03-25T20:46:41+00:00 - [Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer) — 2026-03-25T14:06:13+00:00 - [Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026) — 2026-03-23T19:19:56+00:00 - [Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization) — 2026-03-20T17:38:27+00:00 - [From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll) — 2026-03-11T16:56:12+00:00 - [2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/2025-san-antonio-breast-cancer-symposium-conference-coverage-highlights-podcast) — 2026-03-09T18:50:16+00:00 - [Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions](https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions) — 2026-03-09T17:28:43+00:00 ## Actions Episode pages expose an explicit `request_transcript` action. A page view does not automatically enqueue transcription.